Baxter
Biosimilar developer, United States. 3 development products across 2 molecules: enoxaparin sodium, insulin human.
First approval in the Atlas: Aug 2022, Myxredlin, insulin human (HC)
FDAproducts approved0
EMAproducts approved0
PMDAproducts approved0
HCproducts approved2
CDSCOproducts approved0
EDEproducts registered0
Portfolio by market
| Molecule | Product | FDA | EMA | PMDA | HC | CDSCO | EDE |
|---|---|---|---|---|---|---|---|
| Enoxaparin sodium | Axberi | · | · | · | Jul 2023 | · | · |
| Insulin human | Inpremzia | · | withdrawn | · | · | · | · |
| Insulin human | Myxredlin | · | · | · | Aug 2022 | · | · |
Month shown is the first approval or registration of that product in that market.
Chronology
- HCAug 2022Myxredlin, insulin human
- HCJul 2023Axberi, enoxaparin sodium
Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.
Planning your biosimilar strategy?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.